Inhaled Product Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inhaled Product Characterization
The authors discuss the analysis of the resulting data, focusing on methods for the calculation of mass median ærodynamic diameter, one of the metrics routinely used for comparative testing.


Pharmaceutical Technology
pp. s33-s37

References

1. Stimuli to the Revision Process, "Generalized Simplified Approaches for Mass Median Aerodynamic Determination," Pharmacopeial Forum 36 (3) (2010).

2. M. Copley and J. McDonald, Inhalation 3 (11), 14–17 (2009)

3. W.C. Hinds, Aerosol Technology, Properties, Behavior, and Measurement of Airborne Particles (John Wiley & Sons, 2nd ed., 1999).

4. T.K. Church et al., Proc. Respiratory Drug Deliv. XII, 2, 509–509–512 (2010).

5. D.J. Finney, Probit Analysis (Cambridge University Press, Cambridge, 1971).

6. USP 34–NF 29, Physical Tests and Determinations <601> "Aerosols, Nasal Sprays, Metered-dose Inhalers, and Dry Powder Inhalers," pp. 237–239.

7. D. Lewis, Inhalation (August 2008).

8. Inhalation Report, "How do you calculate MMAD," (2010), http://www.inhalationreport.com/, accessed 10 Oct. 2011.

9. Tougas et al., AAPS Pharm. Sci. Technol., 10 (4) 1276–1285 (2009)

10. Proceedings of EPAG AIM Workshop at DDL 21 (Edinburgh International Conference Center, Dec. 8–10, 2010).

11. P.N. Pantelides et al., proceedings of RDD Europe (Berlin, 2011), pp. 391–395.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here